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Background: The role of IL-7 and pre-TCR signaling during T cell development has been well characterized in
murine but not in human system. We and others have reported that human BM hematopoietic progenitor cells
(HPCs) display poor proliferation, inefficient double negative (DN) to double positive (DP) transition and no
functional maturation in the in vitro OP9-Delta-like 1 (DL1) culture system.
Results: In this study, we investigated the importance of optimal IL-7 and pre-TCR signaling during adult human
T cell development. Using a modified OP9-DL1 culture ectopically expressing IL-7 and Fms-like tyrosine kinase 3
ligand (Flt3L), we demonstrated enhanced T cell precursor expansion. IL-7 removal at various time points during
T cell development promoted a slight increase of DP cells; however, these cells did not differentiate further and
underwent cell death. As pre-TCR signaling rescues DN cells from programmed cell death, we treated the culture
with anti-CD3 antibody. Upon pre-TCR stimulation, the IL-7 deprived T precursors differentiated into CD3
+TCRαβ+DP cells and further matured into functional CD4 T cells, albeit displayed a skewed TCR Vβ repertoire.
Conclusions: Our study establishes for the first time a critical control for differentiation and maturation of adult
human T cells from HPCs by concomitant regulation of IL-7 and pre-TCR signaling.
Keywords: T cell development, Interleukin-7, T cell receptor, Vbeta repertoireBackground
Generation of mature human T cells from adult bone
marrow (BM) CD34+HPCs in vitro may overcome two
major limitations in T cell therapy, namely HLA dispar-
ity and immune tolerance. Patients undergoing chemo-
therapy or with HIV infection suffer from prolonged
lymphodepletion leading to opportunistic infections and
mortality [1]. Hematopoietic stem cell transplant
(HSCT) has been used to reconstitute the immune sys-
tem in such patients [2]. However, T cells take the long-
est time to recover after HSCT [2]. Thus ex vivo
differentiation of T cells using an in vitro OP9 stromal
cell line expressing Notch ligand, Delta like-1 (DL1), has
been of tremendous interest [3-5]. Recent reports* Correspondence: lchang@mgm.ufl.edu
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reproduction in any medium, provided the orshowed that the OP9DL1 stromal cell culture system
established by Zuniga-Pflucker can support terminal
maturation of cord blood (CB) and post natal thymus
derived CD34+HPCs [6,7]. In case of immune rejection
of CB HPCs due to HLA disparity or limited availability,
BM CD34+HPCs may serve as a convenient source as
they can be obtained from patient’s own BM [8,9]. We
and others have demonstrated that adult BM-derived
CD34+HPCs, from both normal adults and patients
undergoing chemotherapy, yields a low number of T cell
precursors in vitro [10-12]. T cell development of adult
human BM derived CD34+HPCs in the OP9 DL1 culture
system is less well studied due to low cellular yields
when compared to the CB counterparts. In addition, ter-
minal T cell differentiation from adult human BM
derived CD34+HPCs in vitro has not yet been demon-
strated [10,13].
We have previously reported that lentivector-modified
OP9 cell lines expressing various cytokines and growth
factors supported enhanced HPC and dendritic celld. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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come the limited proliferation of BM HPCs in vitro, we
modified a previously defined LmDL1 cell line (Lentivec-
tor-modified OP9 expressing DL1) [10], to ectopically
express T cell developmental factors IL-7 and Flt3L, and
established LmDL1-FL7 cell line. We found that
LmDL1-FL7 provided a proliferative advantage to adult
BM CD34+HPCs over LmDL1 cell line supplemented
with soluble recombinant hIL-7 and hFlt3L.
During T cell development, the CD34+CD8-CD4- double
negative (DN) thymocytes differentiate through CD3-CD8+
immature single positive stage (ISP) in mice and CD3-CD4+
ISP in humans, followed by CD3loCD4+CD8+ double posi-
tive (DP), CD3+TCRαβ+DP and then CD3+TCRαβ+CD4+
or CD8+ mature single positive T cells [15,16]. We observed
that the transition of CD3lo DP to CD3+TCRαβ+ DP stage,
an intermediate stage that precedes the terminal maturation
to CD8 or CD4 T cell lineage, is inefficient during adult BM
T cell development in vitro [17]. IL-7 plays an inhibitory
role during DN to DP transition in mice [18-22] and signal-
ing via CD3/Pre-TCR complex plays a permissive role in
transition from CD3lo DP to CD3+ TCRαβ+ DP [23-25].
Thus, we hypothesized that the inefficient pre-TCR
signaling is either due to continued presence of IL-7 or due
to inefficient stimulation via CD3 receptor. Here we report
that intermittent IL-7 withdrawal alone did not result in ef-
ficient differentiation to CD3+TCRαβ+ DP stage. Import-
antly, taking a combination approach of IL-7 withdrawal
and activating pre-TCR signaling using anti-CD3/CD28
antibodies, we demonstrate for the first time in vitro dif-
ferentiation of adult BM HPCs to CD3+TCRαβ+ DP
stage and subsequent functional maturation of CD4 T
cells. Our findings provide a better understanding of the
factors involved in proliferation and differentiation of BM
derived HPCs to mature T cells in vitro.Results
OP9-DL1 cells ectopically expressing Flt3L and IL-7
support enhanced T cell precursor expansion
The previously established mouse OP9-DL1 cell line,
LmDL1 [10], was infected with lentivectors expressing
human Flt3L, or both Flt3L and IL-7, to generate LmDL1-
FL and LmDL1-FL7 cell lines, respectively (Figure 1A).
RNA was harvested and analyzed by semi-quantitative
RT-PCR to confirm transgene expression in these cell
lines (Figure 1B). We confirmed surface expression of
DL1 on all three cell lines, LmDL1, LmDL1-FL and
LmDL1-FL7 (Figure 1C). Both LmDL1-FL and LmDL1-
FL7 expressed high levels of Flt3L on cell surface and in
culture as determined by flow cytometry and ELISA, re-
spectively (Figure 1D). The secretion of IL-7 by LmDL1-
FL7 was measured via ELISA to be in the range of
10–14 ng/mL after 48 hr of culture (Figure 1E).To examine the differentiation and expansion poten-
tial of adult human BM CD34+ HPCs co-cultured
with LmDL1 exogenously supplemented with recom-
binant human Flt3L (5 ng/mL) and IL-7 (5 ng/mL),
or co-cultured with LmDL1-FL7, we determined the
proliferation rate of the incubated cells by counting
total number of suspension cells at various time
points in three independent experiments. The result
showed that CD34+ HPCs cells, when co-cultured
with LmDL1-FL7 for 35 days, expanded up to five
fold more than those co-cultured with LmDL1 supple-
mented with recombinant Flt3L and IL-7 (Figure 1F,
representative of three donors). Thus, LmDL1-FL7
was superior to LmDL1 in supporting T cell precursor
proliferation.Adult BM CD34+ HPCs co-cultured on LmDL1-FL7 or
LmDL1 supplemented with IL-7 and Flt3L follow similar T
cell differentiation kinetics but do not undergo functional
T cell maturation
Next, we analyzed surface expression of CD8, CD4, CD7,
CD1a, CD3, TCRαβ and TCRγδ of the differentiating cells
in the two co-culture systems. Kinetics of CD8, CD4, CD7
and CD1a were comparable between the two systems. We
observed CD4 ISP from day 5 (not shown) to day 15, and
increased CD8 ISP after day 20 (Figure 2). T cell lineage
commitment from HPCs is defined by upregulation of
CD7, followed by CD1a expression which is decreased
upon further maturation. A schematic illustration of the
predicted key events and phenotypes of developing T cell
precursors is shown at top of Figures 2 and 3. We detected
surface CD7 on day 15 (data not shown), and peaked ex-
pression of CD7 and CD1a around day 42, followed by a
gradual decrease of CD1a. Due to the low cell number in
the LmDL1+ IL-7 + Flt3L coculture, we had limited cells
for analysis in the early time points. In both systems, DP
cells appeared around day 35 and decreased by day 56.
The timing of appearance of CD8 ISP and DP varied de-
pending on the donor, and was similar between the two
systems. The rapid expansion of T cell precursors in co-
culture with LmDL1-FL7, which continuously produced
Flt3L and IL-7, was accompanied by a slower transition
into DP and CD3 positive stage, as both DP cells and CD3
surface expression were detected at lower levels in
LmDL1-FL7 co-culture than in LmDL1+ IL-7 + Flt3L
coculture (Figures 2 & 3). Nevertheless, neither system
produced CD3hiTCRhi CD4 or CD8 cell population
(Figure 3). The analysis of TCRγδ surface markers detected
no γδ lineage diversification in LmDL1-FL7 co-culture but
some in LmDL1+ IL-7 + Flt3L (Figure 3 bottom). Thus,
we conclude that no functionally mature T cells could be
generated from the adult BM-derived CD34+ HPCs in the
in vitro cultures.
Figure 1 Enhanced proliferation of T cell precursors on LmDL1-FL7. A, Lentivector constructs expressing mouse DL1, human IL-7 and
human Flt3L. B, qRT-PCR analysis for DL-1, Flt3L, and IL-7. C & D, Flow cytometry analysis of mDL-1 (C) and Flt3L (D) surface expression in the
various OP9 cell lines. ELISA analyses for Flt3L (D) and IL-7 (E) production. F, Growth kinetics of developing T cells from adult human BM-derived
CD34+ HPCs on LmDL + IL-7 + Flt3L versus LmDL1-FL7 with p value indicated.
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transition
In murine T cell development, IL-7 plays a negative role
during transition of DN to DP T cells [18-22]. Human thy-
mocytes have been reported to lose IL-7 dependency upon
reaching CD7/CD1a DP stage [20]. We found that day 21
cells were always negative for CD1a expression; hence we
chose this time point for IL-7 deprivation to ensure that
the cells were in IL-7 dependent phase of development.
To assess the effect of IL-7 deprivation on DN to DP tran-
sition, we cultured adult CD34+ HPCs on LmDL1-FL7 for
21 days, followed by continued presence (IL-7 present) or
deprivation (IL-7 deprived) of IL-7, i.e., on LmDL1-FL7 or
LmDL1-Flt3L, for additional 10–15 days and analyzed the
expression of CD7, CD1a, CD4, CD8, CD3, TCRαβ and
TCRγδ. We observed a decline in cell survival post IL-7
withdrawal indicative of IL-7 dependence (Figure 4A,open circles). We detected an increase in IL-7Ra expres-
sion upon IL-7 withdrawal (LmDL1-Flt3L or LmDL1+
Flt3L, IL-7 deprived, Figure 4 B, C, far right). Additionally,
we observed an increase in percentage of DP cells; how-
ever, these cells lacked CD3hi TCRαβhi phenotype (Figure 4
B, C). Thus, IL-7 deprivation alone is not sufficient to in-
duce CD3hi TCRαβhi DP transition of adult human T cell
precursors on the OP9 culture system.
IL-7 withdrawal does not increase T cell receptor excision
circle (TREC) in the developing T cell precursors
During T cell development, DN T cell precursors re-
arrange their TCR beta chain first, which is expressed with
pre-TCR alpha to form a pre-TCR complex [26]. Signaling
via Pre-TCR complex results in allelic exclusion at TCRβ
locus, but initiates rearrangement at the TCRα locus and
promotes DP transition [27]. Rearrangement at the TCRα
Figure 2 Flow cytometry analyses of expression kinetics of CD8, CD4, CD7, and CD1a of the developing T cells under LmDL1 + IL-7 +
Flt3L or LmDL1-FL7 co-culture condition. Schematic illustration of key stages of T cell development is shown at top. Adult human BM
CD34+ HPCs were plated on LmDL1-FL7 or LmDL1 + IL-7 + Flt3L and surface expression of CD8, CD4, CD7 and CD1a was examined over time as
depicted. The percentages of stained cells are indicated in the flow graph quadrons. ND, not done, due to insufficient amount of developing
T cells from the early time points of the LmDL1 + IL-7 + Flt3L coculture.
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mal circular piece of DNA formed due to excision of delta
locus upon TCRα rearrangement [28]. In order to assess
the frequency of αβ precursors, we analyzed TREC con-
tent in the developing T cell precursors by genomic PCR.
The results showed that cells from day 0 and day 25 were
negative, but from day 30 were positive for TREC
(Figure 5A). We quantified TREC via quantitative PCR
analysis using cloned TREC and RAG2 as standards
(Additional file 1) [29]. Our results showed that < 1% cells
were positive for TREC on Day 30, and IL-7 deprivation
had no effect on TREC content (Figure 5B). RT-PCR ana-
lysis of RNAs showed that this was not due to the lack of
RAG or TCF1/LEF gene expression (Figure 5C). This re-
sult suggests that only a small percent of cells underwent
rearrangement at TCRα locus in the in vitro system.
Adult human HPCs can differentiate to DP T cells and
adopt a CD4 T cell lineage in vitro upon IL-7 deprivation
followed by anti-CD3 stimulation
Signaling via pre-TCR complex, composed of TCRβ,
pre-TCRα and CD3 is crucial for αβ T cell development[27,30]. Pre-TCR is thought to signal in a ligand inde-
pendent fashion, possibly through oligomerization
[31,32]. Pre-TCR signaling can be mimicked by anti-
CD3 antibody stimulation, as in vivo administration of
anti-CD3 antibody induces DN to DP transition in
Rag2−/− pre-Tα−/− mice [25,33]. Also, treatment of fetal
thymus organ culture (FTOC) from TCRβ−/−, Rag2−/−
or SCID mice with anti-CD3 antibodies induces DN to
DP transition [24,25]. Thus, we tested if anti-CD3
stimulation of T cell precursors obtained from LmDL
co-cultures can induce differentiation to DP stage. In
order to maximize cell-cell contact for efficient stimula-
tion, we transferred cells of both IL-7 present and IL-7
deprived groups to U bottom 96 well plates, in a stromal
cell free environment and supplemented with anti-CD3/
CD28 antibody-conjugated beads. We found that IL-7
deprived precursors proliferated upon anti-CD3 engage-
ment but IL-7 present group did not, as demonstrated
by the fold increase in cell number and intracellular
Ki67 staining (Figure 6 A, B). On the other hand, TCR
activation of the IL-7 present group did not induce prolif-
eration. Additionally, percentage of TREC positive cells
Figure 3 Flow cytometry analyses of expression kinetics of CD3, TCRαβ and TCRγδ of the developing T cells under LmDL1 + IL-7 +
Flt3L or LmDL1-FL7 co-culture condition. Schematic illustration of key stages of T cell development is shown at top. T cell markers CD3,
TCRαβ, and TCRγδ were analyzed for the developing T cells under the two different co-culture conditions up to 56 days. ND, not done, due to
insufficient amount of developing T cells from the early time points of the LmDL1 + IL-7 + Flt3L coculture.
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lated group of cells, indicating increased TCRα rearrange-
ment (Figure 6C).
We next examined T cell maturation markers 2 weeks
post stimulation after deprivation of IL-7. We observed
low CD3 expression and no TCRαβ expression in IL-7
present and anti-CD3 stimulated group (Figure 7A, i & iii).
Interestingly, anti-CD3 stimulated cells from the IL-7
deprived group displayed a robust transition from CD3lo
TCRαβloDP to CD3+TCRαβ+DP and CD4+ SP T cells
(Figure 7, ii & iv). Additionally, we found that the cells
were mostly negative for CD56 NK cell marker expression
(Additional file 2). The timing of IL-7 deprivation and anti-
CD3 stimulation was critical, as IL-7 deprivation post day
35 and subsequent anti-CD3 simulation did not induce T
cell differentiation and maturation (data not shown). Thus,
we conclude that IL-7 deprivation is necessary but notsufficient to promote DP transition and subsequent anti-
CD3 stimulation plays a critical role in T cell maturation.
To see if the in vitro developed CD4 T cells were functional
T cells, we further assessed effector functions by IFN-γ,
IL-17 and IL-4 secretion in response to PMA and ionomy-
cin. The results showed that upon stimulation, the in vitro
derived CD4 T cells displayed effector T cell functions simi-
lar to that of peripheral blood CD4 T cells (Figure 7B).
Vβ repertoire analysis of the in vitro generated CD4
T cells
To evaluate the TCR diversity of the in vitro-derived T
lymphocytes, we performed Vβ repertoire analysis for 23
Vβ families of human TCR. The in vitro derived CD4+ SP
T cells were stained with the IOTestW panel of antibodies.
The majority of the in vitro differentiated T cells from
adult BM HPCs (four of five different donors) displayed a
Figure 4 The effect of IL-7 withdrawal on T cell differentiation. Adult BM CD34+ HPCs were co-cultured on LmDL1-FL7 for 21 days and
continued on LmDL-FL7 (IL-7 present) or transferred to LmDL-Flt3L (IL-7 deprived) for additional nine days. A, Growth curves for the developing
T cells in the presence or absence of IL-7 after day 21. The cell growth declined markedly upon IL-7 removal at day 21 (depicted by open circles,
data represents 4 independent experiments). B, Analysis of T cell markers in the T cell development cultures with or without IL-7 withdrawal after
day 21. C, Summary of flow cytometry analysis of surface marker CD4CD8DP, CD4, and IL-7Ra in the developing T cells with (LmDL1-FL7) or
without IL-7 (LmDL1-Flt3L), and p values were determined as shown.
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of Vβ 13.2, 9, 20, 5.1, and 8, respectively, (Donors 1 to 4,
marked by * in Figure 8A) as compared with the control
PBMCs, which showed an evenly distributed pattern.
Note that one of the in vitro derived T cells, donor 5,
showed a less skewed Vβ distribution pattern. The quan-
titative analysis of multiple samples is summarized in
Figure 8B. We further examined Vβ distributions of
healthy donor PBMCs stimulated by anti-CD3/CD28 Ab
or PHA for three weeks, and demonstrated that the en-
tire CD4 Vβ clones were evenly expanded without sub-
stantial skewing (not shown). Together, we found thatthe Vβ repertoires of the in vitro-derived CD4 T lym-
phocytes were highly restricted compared with those of
normal adult CD4 T cells.
Discussion
In vitro adult human BM HPC-derived functional T cells
have great potential for therapeutic applications, as this
approach provides donor HLA-matched T cells that may
be genetically engineered to fight infections, cancer or to
treat immunodeficiencies. Murine HPCs, human CB and
post-natal thymic HPCs undergo full maturation in the
OP9-DL1 culture system [34,35]. However, adult human
Figure 5 TCR rearrangement in developing T cell precursors in LmDL1-FL7 co-culture. A, TREC analysis in developing T cells. PCR analysis
for TREC and Rag2 was performed using genomic DNA harvested at the indicated time points from co-cultures under different IL-7 conditions. B,
Quantitative PCR analysis of TREC-positive cells in developing T cells. SYBR Green quantitative PCR analysis of TREC was performed using genomic
DNA isolated from T cell precursors under indicated culture conditions. C, Analyses of Rag1, Rag2, TCF1 and LEF RNA expression. The expression
of the indicated genes was detected by RT-PCR using 1ug of mRNA harvested from day 30 of the developing T cell precursors.
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at CD3loCD4+CD8+ DP stage of T cell development
[10,13]. In this report, we demonstrated that cell-based
IL-7 and Flt3L provided a proliferative advantage to
adult BM HPCs over exogenously supplemented recom-
binant IL-7 and Flt3L. We then took a combination ap-
proach of IL-7 withdrawal and activating pre-TCR
signaling using anti-CD3/CD28 antibodies, whichFigure 6 Increased proliferation and TCR rearrangement of developin
co-stimulation. Adult human HPCs were co-cultured on LmDL1-FL7 for 21
LmDL-Flt3 (IL-7 deprived) for an additional nine days. A, Diminished precur
cells under IL-7 present or deprived conditions were stimulated using anti-
number were determined and significant difference was observed between
the developing T cells with or without IL-7 and stimulated by anti-CD3/CD
donors were included as controls. C, Quantitative PCR analysis of TREC pos
anti-CD3/28 co-stimulation, as compared with control PBMC from healthy dsuccessfully overcame the arrest in CD3loCD4+CD8+ DP
stage and induced differentiation to CD3+TCRαβ+
CD4+CD8+ DP stage, and subsequent maturation to
CD4 T cells. Our findings provide a better understanding
of the factors involved in proliferation and differen-
tiation of adult BM-derived HPCs in vitro.
LmDL1-FL7 was superior in supporting T cell precursor
proliferation when compared to LmDL1 supplementedg T cells upon concomitant IL-7 removal and anti-CD3/CD28
days and continued on LmDL-FL7 (IL-7 present) or transferred to
sor T cell growth upon continued presence of IL-7. Day 21 T precursor
CD3/CD28 beads for an additional two weeks. The fold increases in cell
the two groups (n =5, P = 0.006). B, Intracellular staining for Ki67 of
28 Ab beads. Un-stimulated and stimulated PBMCs from healthy
itive cells in the developing T cell population after IL-7 deprivation and
onors.
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Figure 7 In vitro maturation and functional analysis of CD4 SP T cells upon IL-7 deprivation and anti-CD3/CD28 co-stimulation in the
absence of stromal cell environment. A, Analysis of T cell development kinetics upon IL-7 removal. Diagram of key events and markers for
precursor T cell development is illustrated at top. Adult HPCs were co-cultured with stromal cells for 21 days and continued on with IL-7 (IL-7
present, i and iii) or transferred to culture without IL-7 (IL-7 deprived, ii and iv) for an additional 17 days. The cells were then transferred to 96
well U bottom plates and stimulated with anti-CD3/CD28 beads for an additional 14 days. Representative results of analysis of T cell surface
markers two weeks after stimulation are shown with percentage of cells indicated in the flow graph quadrons. The percentages of CD4+CD3
+TCRαβ+ cell population of four independent T cell development experiments are shown. B, Analysis of effector functions of the in vitro-derived
CD4 T cells. PBMCs of healthy donors and the in vitro-derived CD4 T cells were stimulated using anti-CD3/CD28 beads in the presence of IL-2, IL-
7 and IL-15 for two weeks. Expression of intracellular effector cytokine (IFNγ) and T helper functional markers (IL-4, IL-17) was detected after
Brefeldin A treatment; unstimulated (left panel) or PMA and ionomycin stimulated (right panel) cells were analyzed by antibody staining and flow
cytometry. Note that the small percentage of in vitro-derived CD8+ cells were not CD3+ or viable propagating cells.
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enhanced precursor proliferation on LmDL1-FL7 remains
to be elucidated. It is possible that concentration or cell-
based modifications, or both, could contribute to the
enhanced proliferation. As all three cell lines, LmDL1,
LmDL1-FL and LmDL1-FL7 expressed high levels of
mDL1 (Figure 1), differential DL1 expression level does
not seem to play a role. Flt3L is expressed as a soluble as
well as membrane bound form [36], and glycosylated form
of IL-7 has been reported [37]. Besides soluble factors,
cell-cell interactions play a critical role in T cell develop-
ment. Our results appear to point to the importance of
cell-based modification of cytokines, as use of glycosylated
IL-7 for clinical trials is being considered [38]. Previous
studies demonstrated that a high dose of IL-7 has a
modest effect on increasing the absolute cell number
during T cell development [18,21]. These studies support
our view that exogenously added cytokine dose has
limited effects on T cell development.
While the T cell development potential such as occur-
rence of CD8 ISP and DP cells were comparable for both
culture systems, some differences exist, such as CD3 ex-
pression and development of TCRγδ cells. Cell-free or
cell-cell signaling of the cytokines may account for the
differences in proliferation and differentiation of the two
systems. Nevertheless, differentiation to DP stage was in-
efficient and neither system supported terminal T cell
maturation. Under both culture conditions, precursor
proliferation rate declined beyond 30–35 days suggesting
a discontinued dependence for IL-7 and Notch signals,
consistent with previous reports [39,40], as such,
this culture system alone does not support continued
differentiation of adult human T cell precursors to CD3
and TCRαβ-bearing DP cells.
Signaling through IL-7/IL-7R supports survival and
proliferation through DN3 stage in murine T cell
development and the same is true for human T cell de-
velopment [20,41]. In transgenic mice, expression of
IL-7 under the control of lck promoter at low levels
enhances proliferation of developing αβ T cells, but at
high levels, it reduces proliferation and displays amarked block in DP transition [21]. Recent studies fur-
ther support that IL-7R signals impair differentiation of
CD8 ISP to DP cells in Zap70−/− and IL-7Rα transgenic
mice [22], and IL-7R signals inhibit the expression of
HMG domain transcription factors TCF-1, LEF-1 and
RORγt, factors important for pre-T to DP transition
[22]. In addition, IL-7 suppresses anti-CD3 antibody
induced differentiation to DP stage in fetal thymus organ
culture of Rag1-deficient mice [19]. Thus, we hypothe-
sized that IL-7 withdrawal prior to ISP might be neces-
sary for efficient DP transition. While IL-7 has been
reported to display an inhibitory role in DP transition in
murine T cell development, our results showed that the
intermittent removal of IL-7 in the in vitro co-culture
only had a minimal effect on human T cell DP
transition.
The mechanism by which IL-7 inhibits T cell develop-
ment is unclear. We observed abundant transcripts of
TCF and LEF in T cell precursors at various time points.
Thus, it seems unlikely that IL-7 withdrawal promotes T
cell development by de-repressing transcription of the
above factors. Our data suggest that IL-7 does not in-
hibit TREC formation, neither does it directly inhibit
pre-TCR signaling. Interestingly, an increase in CD4 sur-
face expression post IL-7 withdrawal may play a role in
how these cells respond to anti-CD3 stimulation. As in
human T cell development, CD4ISP precede DP stage, it
is possible that increased CD4 may account for
increased responsiveness to anti-CD3 stimulation. Alter-
native possibilities are, IL-7 mediates its effect through
STAT-5 on transcription of genes necessary for pre-TCR
expression and function, directly inhibits pre-TCR acti-
vation, or interferes with the TGFβ signaling pathway
[42]. Detailed evaluation of these possibilities requires
further investigation.
IL-7 mediates survival and proliferation of DN thymo-
cytes [43]. In addition, IL-7 is required for TCRγδ gene re-
arrangement and also induces TCRβ chain rearrangement
[44-46]. In order to progress to the next DP maturation
stage, DN/ISP thymocytes must seize the rearrangement
and express a functional TCRγδ or TCRαβ [17]. It is
Figure 8 Vβ repertoire analysis of the in vitro-derived CD4 T cells. After anti-CD3/28 stimulation, the in vitro-derived CD4 T cells were surface
stained for 24 Vβ families using the IOTestW Beta Mark TCR Vβ Repertoire Kit. CD3-gated population was evaluated for the expression of Vβ
families of protein. A, TCR Vβ analysis of in vitro developed CD4 T cells of five CD34+ HPC donors versus a control PBMC. B, Summary analysis of
Vβ distributions of four control PBMCs versus five in vitro derived CD4 T cells.
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exclusion, survival and progression to SP stage [27].
Interestingly, in mice IL-7 signaling is inhibited at DP
stage by down-regulating the IL-7Rα. In humans, IL-7R is
expressed but its binding partner γC is down-regulated
and STAT-5 responsiveness is lost [47]. Hence it is tempt-
ing to speculate that IL-7 signaling down-regulation might
be an additional way of terminating rearrangement and
preventing survival of T cells with non-functional TCRs.
As both IL-7 and TCR signaling deliver survival signals,
the down-regulation of IL-7 signaling ensures shutdown
of an alternative survival pathway and selects for cells that
respond to TCR signals. Clearly, the change in IL-7/IL-7R
signaling is physiologically important and the reason for
such regulation might reside on the intracellular signaling
of IL-7/IL-7R on T cell activation and fate decision: prolif-
eration, death or differentiation.
During T cell development, the appearance of ISP is
dominated by CD4 ISP in human and CD8 ISP in mouse;
pre-TCR signals drive proliferation, TCRα rearrange-
ment, followed by the appearance of CD8 ISP in mouse
and CD4 ISP in human. Interestingly, we observed CD8
ISP derived from human CD34 HPCs in vitro; we found
a lack of proliferative burst and minimal rearrangement
in the TCRα locus. Thus, the CD8 ISP may not be true
ISP generated by pre-TCR signals, rather a result of
cytokine-mediated CD8 expression [48].
T cell development is a complex process that involves
multiple checkpoints and three-dimensional architec-
ture composed of multiple cell types and compartments
[49-52]. Our results, as summarized in Figure 9, demon-
strate that signaling via CD3 and cell-cell contact was
sufficient to drive differentiation to DP and subsequent
CD4 lineage commitment in the absence of thymicFigure 9 Schematic illustration of in vitro T cell developmental progra
markers and critical checkpoints of the in vitro developing T cells from adu
are illustrated.environment. As OP9 cells do not express class II
MHC molecules but the developing human thymocytes
do (data not shown), the resulting CD4 cells are most
likely selected by self MHC of the developing thymo-
cytes. This alternate pathway of CD4 T cell develop-
ment has been reported previously, especially in
human T cell development [53,54]. Our study is in
agreement with recent reports demonstrating that
human HPCs when transplanted into immune compro-
mised mice, can develop into CD4 T cells [55-58].
Such T cell development can occur via thymocyte-
mediated selection, and does not require the presence
of professional antigen presenting cells or epithelial
cells expressing MHC-II. The human CD4 T cells
derived from NOD/SCID γC−/− mice receiving trans-
planted human HPCs display diverse v beta repertoire
[56,57]. However, we found reduced diversity under
the in vitro system illustrated by highly skewed vβ rep-
ertoire in most occasions. The three-dimensional envir-
onment in vivo, and the HLA expression on
thymocytes may account for such differences. It is pos-
sible that TCRβ rearrangement and β selection events
are inefficient in this system and the rare cells with
properly arranged TCRs are selected upon anti-CD3
stimulation. Although one could challenge that expan-
sion of contaminating T cells in the initial source of
BM CD34+ HPCs may occur, we do not think this is
possible as the fold increase post anti-CD3 stimulation
would have been in a magnitude of over 300 fold in
two weeks and we should also observed expansion of
CD8 T cells along with CD4 T cells. Thus, even
though lineage commitment to CD4 T cells can be
achieved independent of thymic microenvironment, the
latter is required for establishing a balanced TCRm of adult human CD34+ BM HPCs. The key events, known surface
lt human BM CD34+ HPCs under the stromal cell co-culture condition
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moting CD8 lineage commitment.
Conclusions
IL-7 withdrawal is necessary but not sufficient for fur-
ther differentiation to DP stage, and anti-CD3 stimula-
tion plays a key role in inducing CD3+TCRαβ+DP
transition and subsequent maturation to CD4 T cells.
Our findings further advance the experimental system
required for in vitro modeling of adult human T cell dif-
ferentiation, and will help develop novel approaches to-
ward generating functional T cells from adult HPCs.
Methods
Human CD34+ cells and cell lines
The adult BM CD34+ HPCs from normal donors were
purchased from AllCell Inc. (San Mateo, CA, USA).
Control PBMCs were obtained from Civitan Regional
Blood Center Inc. (Gainesville, FL) reviewed and
approved by University of Florida Health Science Center
Institutional Review Board (#507-1997, UF IRB-01). All
studies involving human subjects are conducted in ac-
cordance with the guidelines of the World Medical
Association's Declaration of Helsinki (most recent revi-
sion). The mouse fetal stromal cells (OP9) were pur-
chased from the American Type Culture Collection
(ATCC, Manassas, VA) and maintained as previously
described [34]. The engineered LmDL1 and LmDL1-FL7
cell lines were generated by transducing cells with lenti-
vectors encoding DL1, Flt3L and IL-7, respectively. The
stromal cells were maintained in α-MEM (Invitrogen/
Gibco BRL, Grand Island, NY) supplemented with 15-
20% fetal bovine serum (FBS, Invitrogen/Gibco BRL)
and 1% Penicillin-Streptomycin (Mediatech Inc.,
Manassas, VA). IL-7 cytokine secretion was measured
by using human IL-7 ELISA kit (Ray Biotech, Inc) and
soluble Flt3L in culture was measured using human
Flt3L ELISA kit (Assay Biotechnology Company, Inc,
Sunnyvale, CA). Cell free supernatants were harvested
from LmDL1 and LmDLFL7 cells cultured for 48 hrs
(80-90% confluent), in a 12 well plate containing 1 ml
of media. The samples were read on model 680 micro-
plate reader (Bio-Rad). The surface expression of mouse
DL1 and Flt3L was analyzed by flow cytometry with Alexa
Fluor 647-conjugated anti-DL1 Ab (Biolegend) and puri-
fied anti-Flt3L Ab (Abcam Inc. Cambridge, MA) conju-
gated with Zenon-Alexa 488 according to manufacturer’s
instructions (Invitrogen).
LmDL1 stromal cell and CD34+ HPC co-culture
The CD34+ HPCs were seeded into 24-well-plate at 1x105
cells/well containing a confluent monolayer of LmDL1 or
LmDL1-FL7 cells. The cocultures were maintained in
complete medium from day 1, consisting of α-MEM with20% FBS and 1% Penicillin-Streptomycin, supplemented
with 5 ng/ml IL-7 (PeproTech, Inc. Rocky Hill, NJ) and
5 ng/ml Flt3L (PeproTech, Inc.) as indicated. The
cocultures were replenished with new media every
2–3 days. The cells in suspension were transferred to a
new confluent stromal monolayer once the monolayer
began to differentiate or when developing cells reached
80-90% confluent. The cells were transferred by vigorous
pipetting, followed by filtering through a 70 μm filter (BD/
Falcon, BD Biosciences, Sparks, MD) and centrifugation at
250 RCF, at room temperature for 10 min. The cell pellet
was transferred to a fresh confluent monolayer. The cells
were harvested at the indicated time points during the T
cell development for analysis.
Monoclonal antibodies and flow cytometry
The surface expression of mouse DL1 and Flt3L was
analyzed by flow cytometry with Alexa Fluor 647-
conjugated anti-DL1 antibody (Biolegend) and purified
anti-Flt3L antibody (Abcam Inc. Cambridge, MA) conju-
gated with Zenon-Alexa 488 according to manufacturer’s
instructions (Invitrogen). The antibodies used for surface
staining of T cell development included CD4 (clone
RPA-T4 Pacific blue), CD8 (clone RPA-T8 PE), CD3
(clone UCHT1, Pacific Blue, clone SK7, PE-Cy7), TCRαβ
(clone T10B9.1A-31, FITC), CD1a (clone HI149, APC),
CD7 (clone M-T701, FITC, PE), and intracellular stain-
ing for Ki67 (clone B56, FITC), and isotype IgG1κ,
which were from BD Biosciences (San Jose, CA). anti-
CD127 (clone 40131-FITC) was from R&D systems
(Minneapolis, MN). Vβ repertoire analysis was per-
formed using IOTestW Beta Mark TCR Vβ Repertoire
Kit according to manufacturer’s instructions (Beckman
Coulter, Fullerton, CA). For flow cytometric staining,
cells were first washed with PBS plus 2% FBS and
blocked with mouse and human serum at 4°C for
30 min. Cells were incubated with antibodies per manu-
facturer’s instructions. For each fluorochrome-labeled
Ab used, appropriate isotype control was included. After
antibody staining, the cells were washed twice and fixed
with 2% para-formaldehyde. Intracellular staining was
performed using BD cytofix/cytoperm kit, according to
the manufacturer’s protocol. Data was acquired using
BD FACS Diva software (version 5.0.1) on a BD FAC-
SAria or a BD LSR and analyzed using the Flowjo soft-
ware (version 7.1.3.0, Tree Star, Inc. Pasadena, TX).
T cell stimulation and effector function analysis
To stimulate naïve T cells, a protocol for long term
stimulation was followed using anti-CD3/CD28 beads
(Dynal/Invitrogen, San Diego, CA) per manufacturer’s
instructions. The cells and the beads were mixed and
plated into a 96 well plate at 37°C for 2–3 days in X-Vivo
20 (Gibco) media, on day 3, 12.5 U of IL-2, 5 ng/ml of
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were cultured for additional 11–12 days. The in vitro
expanded CD4 T cells were stimulated with PMA and
Ionomycin (Sigma-Aldrich, St. Louis, MO), and analyzed
for the release of IFN-γ, IL-4 and IL-17. Briefly the cells
were incubated with 25 ng/ml PMA and 1 μg/ml iono-
mycin for one hour followed by the addition of 6 μg/
ml monensin (Sigma-Aldrich) to inhibit Golgi-mediated
cytokine secretion. After 4–5 hours of incubation, the
cells were harvested and surface stained for CD4 (clone
RPA-T4, Pacific blue), CD8 (clone SK1, APC-Cy7), CD3
(clone SK7 PE-Cy7), CD25 (clone M-A251, PE) and
intracellular stained for IFN-γ (clone 25723.11, FITC),
IL-4 (clone MP425D2, APC), FOXP3 (clone PCH101,
Alexa 647); the above antibodies were from BD Bios-
ciences, and IL-17 (clone 64CAP17, PE) antibody was
from e-Biosciences. The data were collected by flow
cytometry using BD FACSAria and analyzed using
Flowjo.
RT-PCR
RNA was harvested from cells using TRI-Reagent
(Sigma-Aldrich) and 1 ug RNA was reverse transcribed
into cDNA by using Two-step AMV RT-PCR kit (Gene
Choice, MD). The following primers were used for the
PCR: mGAPDH, F (Forward) 5’-TCA CCA CCA TGG
AGA AGG C-3’ and R (Reverse) 5’-GCT AAG CAG
TTG GTG GTG CA-3’; mDL1, F 5’-GCT CTT CCC
CTT GTT CTA ACG-3’ and R 5’-CAC ATT GTC CTC
GCA GTA CC-3’; Flt3L, F 5’-AAG GAT CCG CAG GAT
GAG GCC TTG-3’ and R 5’-CGG CGA CAG GAG
GCA TGA G-3’; IL-7, F 5’-TTC TCG AGT TAT CAG
TGT TCT TTA GTG-3’ and R 5’-AAG CGG CCG CCA
CCA TGT TCC ATG TTT CT-3’; huGAPDH, F 5’-CCG
ATG GCA AAT TCG ATG GC-3’ and R 5’-GAT GAC
CCT TTT GGC TCC CC-3’; hLEF-1, F 5'-CGA CGC
CAA AGG AAC ACT GAC ATC-3' and R 5'-GCA CGC
AGA TAT GGG GGG AGA AA-3'; hTCF-1, F 5'-CGG
GAC AGA GGA CCA TTA CAA CTA GAT CAA GGA
G-3', and R 5'-CCA CCT GCC TCG GCC TGC CAA
AGT-3'; Rag-1, F 5'-CAG CGT TTT GCT GAG CTC
CT-3' and R 5'-GGC TTT CCA GAG AGT CCT C-3';
Rag-2 F 5'-GCA ACA TGG GAA ATG GAA CTG-3' and
R 5'-GGT GTC AAA TTC ATC ATC ACC ATC-3'. After
30 cycles of amplification (95°C for 30 seconds, 55°C for
30 seconds, and 72°C for 60 seconds), PCR products
were separated on a 2% agarose gel.
T cell receptor excision circle (TREC) analysis
The TREC and RAG2 sequences were amplified by
nested PCRs using two outer primers in the first round
PCR, followed by adding two inner primers in the
second round PCR using genomic DNA of PBMCs as
templates, and cloned into pSTblue and verified byDNA sequencing. The two 5’ primers for TREC amplifi-
cation were: outer 5'-AAT CTA GAG CAT GTT GCT
TGA ACT CCT C-3', and inner 5'-AAT CTA GAG TAG
CAT AAT TTC CTG GTT GAC-3'; the two 3’ primers
for TREC amplification were: outer 5'-AAT CTA GAC
CAA GGT GAA TCC TCT GAT C-3', and inner
5'-AAT CTA GAG TCC CAC ACT CCG TGC TG-3'.
The two 5’ primers for RAG2 amplification were: outer
5'-AAG GAT CCA GCT GTG AAT TGC ACA GTC-3',
and inner 5'-AAG GAT CCG CAA TCC TGA CTC
AAA CTA AC-3'; the two 3’ primers for RAG2 amplifi-
cation were: outer 5'-AAG GAT CCA GTT GAA TAG
AAT GGT ACC-3’ and inner 5'-AAG GAT CCG TAA
TCC AGT AGC CTG TCT C-3'. Cell lysates were pre-
pared by proteinase K digestion (100 μg/mL) at 56°C for
1 hr, followed by heat inactivation at 95°C for 10 min-
utes. In brief, 1.5 μL of cell lysates equivalent to 100 ng
DNA or 15,000 cells, were used as template for PCR
amplification. The following primers were used for the
PCR reaction for TREC: F 5’-CAG AGG GGT GCC
TCT GTC A-3’ and R 5’-CTG TGA AAC ACT CCC
CAG C-3’, and RAG2: F 5’-TCT TGG CAT ACC AGG
AGA CA-3’ and R- 5’-AGT GGA ATC CCC TGG ATC
TT-3’. PCR conditions were 95°C for 10 minutes, fol-
lowed by 35 cycles of 95°C for 30 seconds, 55°C (RAG2)
59°C (TREC) for 60 seconds, 72°C for 60 seconds, with a
final extension at 72°C for 10 minutes. PCR products
were analyzed on 1% agarose gel.Statistical analysis
The statistical analysis was performed using Student’s
t-test and GRAPHPAD PRISM 5 software.Additional files
Additional file 1: Optimized PCR condition for Rag2 and TREC
genomic DNA amplification. A, Titration curves of cloned Rag2 and
TREC templates of known concentrations. The standardization condition
was applied to create a log dilution series for each assay. The coefficient
of correlation for Rag2 were R = 0.9993, and for TREC R = 0.9992,
indicating equal amplification of the templates over a range of input
DNA concentrations. B, The equal and comparable slopes established for
Rag2 and TREC PCR.
Additional file 2: Surface phenotype analysis of the in vitro
differentiated CD4 T cells. The T cells developed from adult BM HPCs
in the LmDL1-FL7 co-culture following IL-7 withdrawal and anti-CD3/
CD28 stimulation were analyzed for various surface markers as shown by
flow cytometry, in comparison with control PBMCs.Competing interests
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